Neuropeptide Y Receptor Type 2 (NPY Y2 Receptor or NPY2R) Drugs in Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players, 2022 Update
Powered by
All the vital news, analysis, and commentary curated by our industry experts.
The Neuropeptide Y Receptor Type 2 pipeline drugs market research report outlays comprehensive information on the Neuropeptide Y Receptor Type 2 (NPY Y2 Receptor or NPY2R) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type, that are being developed by companies/universities. It also reviews key players involved in Neuropeptide Y Receptor Type 2 (NPY Y2 Receptor or NPY2R) targeted therapeutics development with respective active and dormant or discontinued projects.
NPY2R Pipeline Drugs Market by Key Therapy Areas
The key therapy areas in the NPY2R pipeline drugs market are metabolic disorders and central nervous system.
NPY2R Pipeline Drugs Market, by Therapy Areas
For more therapy area insights, download a free report sample
Key Mechanism of Actions in the NPY2R Pipeline Drugs Market
The key mechanism of action of the NPY2R pipeline drugs market is Neuropeptide Y Receptor Type 2 Agonist.
Key Routes of Administration in the NPY2R Pipeline Drugs Market
The key route of administration in the NPY2R pipeline drugs market is topical.
Key Molecule Types in the NPY2R Pipeline Drugs Market
The key molecule types in the NPY2R pipeline drugs market are peptide, fusion protein, gene therapy, and synthetic peptide.
NPY2R Pipeline Drugs Market, by Molecule Types
For more molecule type insights, download a free report sample
Key Companies in the NPY2R Pipeline Drugs Market
The key companies in the NPY2R pipeline drugs market are Gila Therapeutics Inc, Spark Therapeutics Inc, Takeda Pharmaceutical Co Ltd, and XL-protein GmbH.
NPY2R Pipeline Drugs Market, by Companies
To know more about the companies, download a free report sample
Neuropeptide Y Receptor Type 2 Pipeline Drugs Market Report Overview
Key Therapy Areas | Metabolic Disorders and Central Nervous System |
Key Mechanism of Actions | Neuropeptide Y Receptor Type 2 Agonist |
Key Routes of Administration | Topical |
Key Molecule Types | Peptide, Fusion Protein, Gene Therapy, and Synthetic Peptide |
Key Companies | Gila Therapeutics Inc, Spark Therapeutics Inc, Takeda Pharmaceutical Co Ltd, and XL-protein GmbH |
Scope
This report provides:
- A snapshot of the global therapeutic landscape for Neuropeptide Y Receptor Type 2 (NPY Y2 Receptor or NPY2R).
- Reviews of targeted therapeutics for Neuropeptide Y Receptor Type 2 (NPY Y2 Receptor or NPY2R) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- Pipeline products based on various stages of development ranging from pre-registration to discovery and undisclosed stages.
- Descriptive drug profiles for the pipeline products which include product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities.
- Reviews of key players involved in Neuropeptide Y Receptor Type 2 (NPY Y2 Receptor or NPY2R) therapeutics and enlists all their major and minor projects.
- Assessment of Neuropeptide Y Receptor Type 2 (NPY Y2 Receptor or NPY2R) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA), and molecule type.
- Summarization of all the dormant and discontinued pipeline projects.
- Reviews of the latest news and deals related to Neuropeptide Y Receptor Type 2 (NPY Y2 Receptor or NPY2R) targeted therapeutics.
Reasons to Buy
- Gain strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Identify emerging players with potentially strong product portfolio and create effective counterstrategies to gain competitive advantage.
- Identify and understand the targeted therapy areas and indications for Neuropeptide Y Receptor Type 2 (NPY Y2 Receptor or NPY2R).
- Identify the use of drugs for target identification and drug repurposing.
- Identify potential new clients or partners in the target demographic.
- Develop strategic initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions effectively by identifying key players and their most promising pipeline therapeutics.
- Devise corrective measures for pipeline projects by understanding the Neuropeptide Y Receptor Type 2 (NPY Y2 Receptor or NPY2R) development landscape.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
Table of Contents
Table
Figures
Frequently asked questions
-
What are the key therapy areas of the NPY2R pipeline drugs market?
The key therapy areas in the NPY2R pipeline drugs market are metabolic disorders and central nervous system.
-
What are the key mechanism of actions in the NPY2R pipeline drugs market?
The mechanism of action in the NPY2R pipeline drugs market is Neuropeptide Y Receptor Type 2 Agonist.
-
What are the key routes of administration in the NPY2R pipeline drugs market?
The route of administration in the NPY2R pipeline drugs market is topical.
-
What are the key molecule types in the NPY2R pipeline drugs market?
The key molecule types in the NPY2R pipeline drugs market are peptide, fusion protein, gene therapy, and synthetic peptide.
-
Which are the key companies in the NPY2R pipeline drugs market?
The key companies in the NPY2R pipeline drugs market are Gila Therapeutics Inc, Spark Therapeutics Inc, Takeda Pharmaceutical Co Ltd, and XL-protein GmbH.
Get in touch to find out about multi-purchase discounts
reportstore@globaldata.com
Tel +44 20 7947 2745
Every customer’s requirement is unique. With over 220,000 construction projects tracked, we can create a tailored dataset for you based on the types of projects you are looking for. Please get in touch with your specific requirements and we can send you a quote.